W88优德中国官方网站 Assisted AZ-CICC in its Investment in Axbio International
2022.07.06
In June 2022, Wuxi AstraZeneca CICC Venture Capital Partnership (L.P.) (“AZ-CICC”) as one of the lead investors completed its Round B investment in Axbio International Limited (“Axbio”). The total amount of this round of investment was approximately USD 100 million. AZ-CICC and Yunfeng Financial were the joint lead investors, CBridge Capital and SDIC were co-investors and 5Y Capital, the original shareholder, increased its shareholding. W88优德中国官方网站 was the sole domestic legal advisor to AZ-CICC, and participated in the investment on its behalf.
Axbio is a leading company involved in the fourth generation of gene sequencers, and its technology path is CCS+ nanopore single molecule sequencing. Its miniaturized mobile single molecule sequencing platform, based on nanopore chips, belongs to the top technology in the field of gene sequencing. The CMOS-based high throughput chip exclusively owned by Axbio makes AXP series sequencing machines developed by AXP. The sequencing machines are comparatively low cost and are faster and smaller, with a single sample boot. They produce test reports quickly, which is an advantage in the burgeoning clinical sequencing market.
W88优德中国官方网站, as AZ-CICC’s legal advisor, participated in the whole process of the legal due diligence investigation. W88优德中国官方网站’s team was involved in the design of the transaction structure, drafted and negotiated the transaction documents, undertook the contract signing and the closing of the Project. W88优德中国官方网站’s rich project experience and professional and meticulous legal services was highly recognized and affirmed by the client and the parties concerned.
PartnersLIU, NingandCAI, Jing (Cathy) led the W88优德中国官方网站 team for this Project and primarily undertook the work. Partners GONG, Mingfang in W88优德中国官方网站’s anti-monopoly team and associate CAI, Juanqi (Jessica) in W88优德中国官方网站’s international trade team also rendered great assistance to this Project.
